I am a resident in Psychiatry at Department of Clinical and Experimental Medicine, University of Catania, Italy and in Cognitive Therapy at Centro Clinico Crocetta, Torino, Italia. My research is mainly focused on mood disorder, in particular Bipolar Disorder (BD), but I am interested in many other fields of mental health, such as the interaction between trauma, metabolic and inflammation disease and psychiatric disorders.

György Németh has been the Neuropsychiatry Global Portfolio Director at Gedeon Richter Plc. since 2020. He is responsible for leading Gedeon Richter’s pillar of neuropsychiatry, which includes chairing global clinical research, development and strategy teams of the field; as well as managing medical-regulatory-marketing issues. He began his carrier at the Medical School of Debrecen University, Department of Neurology and Psychiatry. Later on, he worked as a fellow of Alexander von Humboldt Foundation at the University of Heidelberg, Germany. Afterwards he had different fellowships at the Karolinska Institute in Stockholm, Sweden and at New York University Medical Center in New York, USA. He continued his professional career as a clinical researcher at Knoll AG, Department of CNS R&D, where later, he took over the responsibility as Global Strategic Director for world-wide clinical and regulatory activities, launching among others two blockbuster new chemical entities. His main activities were international leader in the clinical development of drug candidates for the treatment of different neuropsychiatric indications. Between 2002 and 2020 he was the Chief Medical Officer at Gedeon Richter Plc. and was responsible for leading the Medical Division of the company. In 2021 he was promoted to become Neuropsychiatry Global Portfolio Director. One of the success stories under his clinical leadership at Gedeon Richter was that a pioneering antipsychotic (cariprazine) was approved by the FDA. In the meantime, he succeeded in verifying the efficacy of cariprazine in predominantly negative symptoms which was previously lacking therapeutic possibilities as well as in bipolar disorders and major depression. Thus, he instituted and led the clinical developments of a first-in-class drug by using broad spectrum approach. Owing to his comprehensive science operation, he is an active member of umpteen societies including Hungarian, European, and American societies. He is committed to personalized medicine. He has been the President of Hungarian Personalized Medicine Society since its foundation (2010).